Related Experiment Videos

[Clinical significance of gastrointestinal decontamination under protected environment]

T Nagao1, S Yonekura, M Komatsuda

  • 1Fourth Department of Internal Medicine, School of Medicine, Tokai University.

Insights

Prophylactic vancomycin, polymyxin B, and nystatin (VPN) effectively eliminated gut microbes in leukemia patients. This antibiotic regimen reduced infections and febrile days, protecting against endogenous infections.

Area of Science:

  • Oncology
  • Infectious Diseases
  • Microbiology

Background:

  • Endogenous oro-intestinal microbial flora can cause infections in immunocompromised patients, particularly those with leukemia.
  • Protected environments are used to manage patients with compromised immune systems.

Purpose of the Study:

  • To evaluate the efficacy of prophylactic antibiotics for decontamination in leukemia patients undergoing treatment in a protected environment.
  • To assess the impact of antibiotic regimens on microbial flora and infection rates.

Main Methods:

  • Thirty-eight acute leukemia patients and two chronic myelocytic leukemia patients in blast crisis were studied.
  • Patients were assigned to three groups: vancomycin/polymyxin B/nystatin (VPN), polymyxin B/nystatin (PN), or no antibiotics.
  • Intestinal microbial flora, pharyngeal and anorectal bacterial species, febrile days, and infection episodes were monitored.

Main Results:

  • The vancomycin/polymyxin B/nystatin (VPN) regimen nearly eliminated intestinal microbial flora.
  • The VPN and PN groups showed significantly fewer febrile days compared to the no-antibiotic group, especially in patients with low neutrophil counts (<100/µL).
  • The VPN group had the lowest average number of infection episodes per patient.

Conclusions:

  • Prophylactic vancomycin/polymyxin B/nystatin (VPN) administration is effective in eradicating intestinal bacterial flora.
  • VPN decontamination protects against endogenous infections in leukemia patients.
  • Antibiotic decontamination strategies can reduce infection morbidity in immunocompromised patients.

Related Concept Videos